Last updated on November 2014

An Open-label Trial of Intravenous Immune Globulin (IVIG)in Treating Spinocerebellar Ataxias


Brief description of study

An Open-label Trial of Intravenous Immune Globulin (IVIG)in Treating Spinocerebellar Ataxias

Detailed Study Description

The purpose of this study is to learn how Intravenous Immune Globulin (IVIG) will affect Spinocerebellar Ataxia (SCA) symptoms and how it will affect motor and nervous system function in participants Subtypes of SCA to be examined will include SCA types 1, 2, 3, 6, 10 and 11.

Clinical Study Identifier: TX139672

Contact Investigators or Research Sites near you

Start Over

Jessica Shaw

University of South Florida - Morsani Center for Advanced Healthcare
Tampa, FL USA
  Connect »